1 周璟,黄学惠.卵巢癌的治疗现状回顾 .现代肿瘤学,2012,20:1308-1311. 2 Koshiyama M,Matsumura N,Konishi I.Recent concepts of ovarian carcinogenesis:type I and type II.BioMed Res Int,2014:934261. 3 Foster T,Brown TM,Chang J,et al.A review of the current evidence for maintenance therapy in ovarian cancer.Gynecol Oncol,2009,115:290-301. 4 Bast RJ,Feeney M,Lazarus H,et al.Reactivity of a monoclonal antibody with human ovarian carcinoma.J Clin Invest,1981,68:1331-337. 5 Markmann S,Gerber B,Briese V.Prognostic value of Ca 125 levels during primary therapy.Anticancer Res,2007,27:1837-1839. 6 Hellstrom I,Raycraft J,Hayden-Ledbetter M,et al.The HE4 protein is a biomarker for ovarian carcinoma.Cancer Res,2003,63:3695-3700. 7 涂晓波,徐冬梅.人附睾蛋白4与糖类抗原CA125、CA199联合测定对卵巢癌的诊断价值 .中国卫生检验杂志,2014,24:90-94. 8 闫先侠,孙晓,张华.血清人附睾蛋白4联合CA125检测在卵巢癌诊断中的应用.现代检验医学杂志,2015,30:134-136. 9 张丰坤.血清HE4与CA125水平与卵巢癌诊断和预后的相关性分析.基层医学论坛.2016,20:503-504. 10 叶雪,程洪艳,马瑞琼.国产人附睾分泌蛋白4(HE4)ELISA试剂盒与CA125联合诊断上皮性卵巢癌的研究.中国妇产科临床杂志,2014,15:395-397. 11 解肖鹏,张雷.时间分辨荧光免疫分析技术的研究进展 .食品与药品,2012,14:203-206. 12 韩光辉,张丽君,周奇.新型卵巢肿瘤标志物人附睾蛋白 4 的两种定量检测方法的比较与分析.中国妇幼保健,2015,30:2086-2088. 13 卢安.化学发光法的研究进展综述.中国保健营养月刊,2012,22:2967-2968. 14 Kirchhoff C,Habben I,IvellR,et al.A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors.Biol Reprod,1991,45:350-357. 15 Schummer M,Ng WV,Bumgarner R,et al.Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes over expressed in ovarian carcinomas.Gene,1999,238:375-385. 16 刘海伦,程忠平.CA125 不同计算方法在卵巢癌筛查评估及预后方面的作用.现代妇产科进展,2016,25:636-639. 17 王耀楷.人附睾分泌蛋白4和CA125 在卵巢癌早期诊断中的价值.医学综述,2015,21:1700-1702. 18 朱振宁,魏娜,严妮子.HE4 联合 CA125 在卵巢癌早期诊断中的应用价值.现代肿瘤医学,2014,22:623-624.
